Howard Marks weighs whether AI is a bubble, flags speculative valuations and debt risks, and urges selective, moderate ...
Ultragenyx Pharmaceutical and Mereo BioPharma Group saw their shares plummet after ringing out 2025 by announcing the failures of their brittle bone disease candidate setrusumab (UX143) in a pair of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback